Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cardiol Therapeutics Inc (CRDL.TO)

Cardiol Therapeutics Inc (CRDL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 210,445
  • Shares Outstanding, K 68,998
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,128 K
  • 60-Month Beta 0.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.49
Trade CRDL.TO with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.34 +37.61%
on 04/25/24
3.27 -1.53%
on 05/24/24
+0.82 (+34.17%)
since 04/24/24
3-Month
1.81 +77.90%
on 03/12/24
3.27 -1.53%
on 05/24/24
+1.04 (+47.71%)
since 02/23/24
52-Week
0.89 +261.80%
on 06/02/23
3.27 -1.53%
on 05/24/24
+2.33 (+261.80%)
since 05/24/23

Most Recent Stories

More News
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER...

CRDL : 2.35 (+5.38%)
CRDL.TO : 3.22 (+5.57%)
Manufacturing, Housing Due Next Week in Canada

Monday U.S. Featured Earnings Legend Biotech Corporation (NASDAQ: LEGN) (Q1) EPS ...

CRDL.TO : 3.22 (+5.57%)
ORE.TO : 0.73 (-1.35%)
PBH.TO : 89.74 (+0.83%)
LEGN : 41.41 (+4.84%)
STNE : 14.29 (unch)
PHVS : 20.18 (+3.22%)
BABA : 81.26 (+0.57%)
SONY : 80.29 (-0.63%)
CSCO : 46.42 (-0.39%)
TJX : 102.14 (+1.98%)
CPRT : 54.02 (+0.93%)
WMT : 65.38 (+0.83%)
How a Recent M&A Deal Could Catapult a Small-Cap Biotech to New Heights

Cardiol Therapeutics (CRDL), a clinical-stage life sciences company, is researching and developing new drugs to fight inflammation and scarring in the heart. Their main drug, CardiolRx™, is b

NVO : 136.04 (+0.35%)
CRDL : 2.35 (+5.38%)
CRDL.TO : 3.22 (+5.57%)
Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx™ granted U.S. FDA Orphan...

CRDL : 2.35 (+5.38%)
CRDL.TO : 3.22 (+5.57%)
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Topline Results Expected in Q2 2024This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"),...

CRDL : 2.35 (+5.38%)
CRDL.TO : 3.22 (+5.57%)
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024)...

CRDL : 2.35 (+5.38%)
CRDL.TO : 3.22 (+5.57%)
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL : 2.35 (+5.38%)
CRDL.TO : 3.22 (+5.57%)
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL : 2.35 (+5.38%)
CRDL.TO : 3.22 (+5.57%)
Stocks in play: Cardiol Therapeutics Inc.

Announced that Massachusetts General Hospital has been initiated and is eligible to enroll patients ...

CRDL.TO : 3.22 (+5.57%)
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024Toronto, Ontario--(Newsfile Corp. - December 5, 2023) - Cardiol Therapeutics...

CRDL : 2.35 (+5.38%)
CRDL.TO : 3.22 (+5.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol...

See More

Key Turning Points

3rd Resistance Point 3.50
2nd Resistance Point 3.39
1st Resistance Point 3.30
Last Price 3.22
1st Support Level 3.10
2nd Support Level 2.99
3rd Support Level 2.90

See More

52-Week High 3.27
Last Price 3.22
Fibonacci 61.8% 2.36
Fibonacci 50% 2.08
Fibonacci 38.2% 1.80
52-Week Low 0.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar